

Supplementary material

Januszek R, Zabojszcz M, Cyran-Stemplewska S, et al. Impact of psoriasis on ticagrelor platelet activity versus clopidogrel in patients with chronic coronary syndromes treated via percutaneous coronary intervention. Pol Arch Intern Med. 2021; 131: 16105. doi:10.20452/pamw.16105

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Patients and methods

The severity of local lesion advancement is presented as the percentage of body-surface area (BSA), which is characterised by good repeatability [M1]. Another scale used in the current study was the “Psoriasis area and severity index” (PASI), which was developed to assess the effectiveness of oral retinoids in the treatment of psoriasis and as an indicator that takes the extent and intensity of skin lesions into account [M2]. While the Physicians' Global Assessment (PGA) scale is most commonly used along with PASI and BSA, the 5-point scale usually does not allow to consider the area and location of skin lesions [M3]. The quality of life in this narrow group of patients was assessed by the “Dermatology life Quality index” (DLQI), which is the most widely used scale for the evaluation of life quality among patients with psoriasis [M4]. Platelet reactivity was assessed as P2Y12 reaction units (PRU) by the VerifyNow assay (Accriva Diagnostics, San Diego, CA), measured pre-LD and after 30 days of treatment with the P2Y12 inhibitor (clopidogrel or ticagrelor) [M5-6].

References:

M1. Spuls PI, Lecluse LL, Poulsen ML, et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. *J Invest Dermatol.* 2010; 130: 933-943.

M2. Fredriksson T., Pettersson U. Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. *Dermatologica*. 1979; 158: 60-64.

M3. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. *J Am Acad Dermatol*. 2012; 66: 369-375.

M4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994; 19: 210-216.

M5. Angiolillo DJ, Franchi F, Waksman R, et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI. *J Am Coll Cardiol*. 2016; 67: 603-613.

M6. van Werkum JW, Harmsze AM, Elsenberg EH, et al. The use of the VerifyNow system to monitor antiplatelet therapy. *Platelets*. 2008; 19: 479-488.

Table S1 Baseline characteristics

Variable	Clopidogrel group (n=32)				Ticagrelor group (n=31)			
	Overall	Psoriasis (n = 10)	No-psoriasis (n = 22)	<i>P</i> value	Overall	Psoriasis (n = 8)	No-psoriasis (n = 23)	<i>P</i> value
Age, years	67.5 (58.2, 73.7)	64.5 (40; 74)	68 (62.7; 74.7)	0.74	62 (59; 70)	60.5 (51.5, 64)	62 (59; 70)	0.40
Gender, males	25 (78.1%)	8 (80%)	17 (77.3%)	1	24 (77.4%)	6 (75%)	17 (73.9%)	1
BMI, kg/m ²	29 (24.9; 34)	29.5 (24.2; 33.5)	29 (26.4; 38.6)	0.92	26.8 (22.2; 30.3)	22.5 (22; 29.2)	28.9 (25.3; 31.4)	0.33
Treatment with ASA	31 (96.9%)	10 (100%)	21 (95.4%)	1	30 (96.8%)	8 (100%)	22 (95.65%)	1
Diabetes mellitus	15 (46.9%)	6 (60%)	9 (40.9%)	0.94	11 (35.5%)	3 (37.5%)	8 (34.8%)	1
Hyperlipidaemia	31 (96.9%)	9 (90%)	22 (100%)	0.62	28 (90.3%)	7 (87.5%)	21 (91.3%)	1

Data are presented as median (Q1; Q3) or as number (percentages)

ASA: acetyl-salicylic acid; BMI: body-mass index

Table S2 Selected indices regarding psoriasis in the ticagrelor and clopidogrel groups

Variable	Clopidogrel group and psoriasis (n = 10)	Ticagrelor group and psoriasis (n = 8)	P value
Years of psoriasis	20 (8; 33.5)	15 (10.5; 22.5)	0.48
BSA	10.5 (3.5; 15)	11.5 (6.7; 19.7)	0.72
PASI	4.8 (3.4; 11.4)	10 (3.6; 11.5)	0.62
PGA			
0	0 (0%)	1 (12.5%)	0.28
1	1 (10%)	1 (12.5%)	
2	5 (50%)	0 (0%)	
3	3 (30%)	3 (37.5%)	
4	1 (10%)	3 (37.5%)	
DLQI	13 (5.7; 18.2)	17 (11.2; 26.7)	0.42
Psoriatic arthritis	4 (40%)	2 (25%)	0.63
Topical medication	3 (30%)	3 (37.5%)	1
Methotrexate	2 (20%)	3 (37.5%)	0.6
Ciclosporin	1 (10%)	0 (0%)	1
Acitretin	1 (10%)	0 (0%)	1
Biologic treatment	8 (80%)	3 (37.5%)	0.14

Data are presented as median (Q1; Q3) and number (percentages)

BSA, body surface area; DLQI, dermatology life quality index; PASI, psoriasis area and severity index; PGA, physician's global assessment

Figure S1 Patients' flow chart

